{"title":"Inflammation and coagulation in HIV infection contributes significantly to patient mortality","authors":"W. Stevens","doi":"10.2217/17584310.3.2.135","DOIUrl":null,"url":null,"abstract":"Evaluation of: Kuller LH, Tracey R, Belloso W et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLOS Med. 5(10), e203 (2008). The authors of this paper investigate a number of biomarkers associated with inflammation (high sensitivity C-reactive protein, IL-6, amyloid A, and amyloid P) and coagulation (D-dimer and prothrombin fragment 1+2) in the Strategies for Management of Antiretroviral Therapy (SMART) trial. In the SMART study an increased risk of all-cause mortality was demonstrated in the therapy interruption arm, as compared with standard practice of continuous antiretroviral treatment. Kuller and colleagues demonstrated that IL-6 and D-dimer levels were strongly associated with all-cause mortality. The authors postulate that HIV leads to activation of inflammation and coagulation increasing the risk of death in HIV-infected individuals and that interrupting antiretroviral treatment increases this risk.","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"107 1","pages":"135-139"},"PeriodicalIF":0.0000,"publicationDate":"2009-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/17584310.3.2.135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Evaluation of: Kuller LH, Tracey R, Belloso W et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLOS Med. 5(10), e203 (2008). The authors of this paper investigate a number of biomarkers associated with inflammation (high sensitivity C-reactive protein, IL-6, amyloid A, and amyloid P) and coagulation (D-dimer and prothrombin fragment 1+2) in the Strategies for Management of Antiretroviral Therapy (SMART) trial. In the SMART study an increased risk of all-cause mortality was demonstrated in the therapy interruption arm, as compared with standard practice of continuous antiretroviral treatment. Kuller and colleagues demonstrated that IL-6 and D-dimer levels were strongly associated with all-cause mortality. The authors postulate that HIV leads to activation of inflammation and coagulation increasing the risk of death in HIV-infected individuals and that interrupting antiretroviral treatment increases this risk.